Drug
Eliglustat clinical trials
Also written Genz-112638, Cerdelga and GZ385660.
- studies test it
- 18
- open now
- 3
- in phase 3
- 4
- first study started
- 2006
Keep track of what changes. Save the eliglustat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
18 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2018 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 3
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 4
Genzyme, a Sanofi Company (10) · Sanofi (4) · Chinese PLA General Hospital (2) · National Taiwan University Hospital (1) · Peking Union Medical College Hospital (1)
Often tested with
Tested in the same studies.
Metoprolol (1) · Digoxin (1) · Regorafenib (1) · Immune Checkpoint Inhibitors (1)
Studies
Open first, then newest update. How each study uses eliglustat is read from its arms, and is right about nine times in ten.
Testing it · 18
- GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.RecruitingPhase 2Chinese PLA General HospitalNCT06558773Written as Eliglustat+Immune checkpoint inhibitor
- GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.Not yet recruitingEarly Phase 1Chinese PLA General HospitalNCT07090538Written as Eliglustat
- Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3Not yet recruitingPhase 2Peking Union Medical College HospitalNCT06523517Written as Eliglustat Tartrate Capsules
- A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor MetabolizersCompletedPhase 1SanofiNCT06188325Written as Eliglustat
- A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the MouthCompletedPhase 1SanofiNCT06193304Written as Eliglustat
- A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male ParticipantsCompletedPhase 1SanofiNCT06143904Written as Genz-112638
- Eliglustat on Gaucher Disease Type IIIBCompletedNot applicableNational Taiwan University HospitalNCT03519646Written as Eliglustat
- Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 StudiesCompletedPhase 3Genzyme, a Sanofi CompanyNCT02536755Written as Eliglustat, GZ385660
- A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat TartrateCompletedPhase 1SanofiNCT02536937Written as eliglustat
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)CompletedPhase 3Genzyme, a Sanofi CompanyNCT00891202Written as Eliglustat tartrate
- A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher PatientsCompletedPhase 2Genzyme, a Sanofi CompanyNCT00358150Written as Eliglustat tartrate
- A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat TartrateCompletedPhase 1Genzyme, a Sanofi CompanyNCT02536911Written as eliglustat
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)CompletedPhase 3Genzyme, a Sanofi CompanyNCT01074944Written as Eliglustat tartrate
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)CompletedPhase 3Genzyme, a Sanofi CompanyNCT00943111Written as Eliglustat tartrate
- Taste Evaluation of Different Liquid Formulations With EliglustatCompletedPhase 1Genzyme, a Sanofi CompanyNCT02422654Written as eliglustat
- Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy AdultsCompletedPhase 1Genzyme, a Sanofi CompanyNCT01659944Written as Eliglustat
- A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult SubjectsCompletedPhase 1Genzyme, a Sanofi CompanyNCT01452542Written as Eliglustat, common blend proposed commercial formulation
- A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy AdultsCompletedPhase 1Genzyme, a Sanofi CompanyNCT01357811Written as eliglustat; digoxin
Given in every arm · 2 — eliglustat is usual care beside what is tested
- Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3CompletedPhase 3SanofiNCT03485677Written as Eliglustat GZ385660
- GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid TumorCompletedPhase 1Chinese PLA General HospitalNCT04944888Written as Eliglustat
Codes
What other systems call eliglustat · ClinicalTrials.gg INT005159
- MeSH (NLM) C522917eliglustatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DR40J4WA67ELIGLUSTATConfirmed FDA, NLM, Wikidata
- RxNorm 1547220Confirmed FDA, Wikidata
- Wikidata Q21011224eliglustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96282EliglustatOne source FDA
- DrugBank DB09039One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522917 | eliglustat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DR40J4WA67 | ELIGLUSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1547220 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011224 | eliglustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96282 | Eliglustat | One source FDA |
| DrugBank | DB09039 | — | One source Wikidata |
Also registered as eliglustat tartrate (UNII N0493335P3 · RxNorm 1547219).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.